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Abstract: 
Great efforts have been made to identify promising antigens and vaccine 
formulations against schistosomiasis. Among the previously described Schistosoma 
vaccine candidates, cyclophilins comprise an interesting antigen that could be used for 
vaccine formulations. Cyclophilin A is the target for the cyclosporine A, a drug with 
schistosomicide activity, and its orthologue from Schistosoma japonicum induces a 
protective immune response in mice. Although Schistosoma mansoni cyclophilin A also 
represents a promising target for anti-schistosome vaccines, its potential to induce 
protection has not been evaluated. In this study, we characterized the cyclophilin A 
(SmCyp), initially described as Smp17.7, analyzed its allergenic potential using in vitro 
functional assays, and evaluated its ability to induce protection in mice when 
administered as an antigen using different vaccine formulations and strategies. Results 
indicated that SmCyp could be successfully expressed by mammalian cells and bacteria. 
The recombinant protein did not promote IgE-reporter system activation in vitro, 
demonstrating its probable safety for use in vaccine formulations. T and B-cell epitopes 
were predicted in the SmCyp sequence, with two of them located within the active 
isomerase site. The most immunogenic antigen, SmCyp (107–121), was then used for 
immunization protocols. Immunization with the SmCyp gene or protein failed to reduce 
parasite burden but induced an immune response that modulated the granuloma area. In 
contrast, immunization with the synthetic peptide SmCyp (107–121) significantly 
reduced worm burden (48–50%) in comparison to control group, but did not regulate 
liver pathology. Moreover, the protection observed in mice immunized with the 
synthetic peptide was associated with the significant production of antibodies against 
the SmCyp (107–121) epitope.  Therefore, in this study, we identified an epitope within 
the SmCyp sequence that induces a protective immune response against the parasite, 
thus representing a promising antigen that could be used for vaccine formulation against 
schistosomiasis.  
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1. Introduction 
Schistosomiasis, a debilitating disease caused by flatworm parasites of the Schistosoma 
genus, affects more than 200 million individuals worldwide and causes 1.9 million 
DALYs (disability-adjusted life years) globally (GBD 2016 DALYs and HALE 
Collaborators, 2017; WHO, 2018). Due to the inadequacy of the current control 
strategy, which is based on chemotherapy with praziquantel (PZQ) to limit disease 
transmission, vaccination represents a promising alternative. In fact, a recent study 
based on a mathematical model demonstrated that even a vaccine resulting in partial 
protection could interrupt transmission within approximately 18 years (Stylianou et al., 
2017).   
 
In searching for antigens that could be used in vaccine formulations, the cyclophilins 
have arisen as candidates. Cyclophilins (Cyps) or peptidyl-prolyl cis-trans isomerases 
are highly conserved ubiquitous proteins that carry out a wide range of functions 
including protein folding, trafficking and assembly (Fischer et al., 1989; Schonbrunner 
et al., 1991; Trandinh et al., 1992; Gothel et al., 1999).  
 
Cyps are present in different compartments of the cell such as the cytosol, mitochondria, 
nucleus, or extracellular matrix in many different isoforms (Handschumacher et al., 
1984; Rassow et al., 1995; Hoffmann and Schiene-Fischer, 2014; Rajiv et al., 2018). In 
Schistosoma mansoni, Kiang et al. (1996) showed that cyclophilin is located in the 
tegument, muscle layers, intestinal epithelium, and interior of the worm, therefore, it is 
in contact with the host immune system. Unlike the majority of species in which 
cyclophilin A is the major isoform, S. mansoni cyclophilin A is less abundant than the 
cyclophilin B isoform (Bugli et al., 1998).   
 
In general, cyclophilins are specific protein targets for the immunosuppressive drug 
cyclosporin A (CsA).  This drug can facilitate the complete elimination of a wide range 
of parasites including schistosomes, even if administered only once during experimental 
infection (Bueding et al., 1981; Chappell et al., 1987; Chappell et al., 1988). In S. 
mansoni, the cyclosporin/cyclophilin complex inhibits translocation of the parasite 
nuclear factor protein, homolog to the human NFAT (nuclear factor of activated T-cells) 
to the nucleus, thereby inhibiting parasite development (Serra et al., 1999). Despite its 
role in parasite development and its accessibility to the host immune system, S. mansoni 
cyclophilin has never been tested in vaccine formulations against schistosomiasis. 
 
However, Han et al. (2012) demonstrated that Schistosoma japonicum cyclophilin A 
induces a protective immune response in immunized mice (Han et al., 2012). Further, 
the immunization of mice with a recombinant form of S. japonicum cyclophilin A 
provided further support for the importance of this protein in parasite development, 
since the immune response elicited by rSjCypA immunization in mice was found to 
impair S. japonicum development (Han et al., 2012). 
Although S. mansoni cyclophilin A (SmCyp) is thought to be a potential target for anti-
schistosome vaccines, its ability to induce protection is not clear. Here, we characterized 
this antigen, analyzed its allergenic potential based on an in vitro functional assay, and 
evaluated its ability to induce protection in mice when used as an antigen with different 
vaccine formulations and strategies.  The safety of SmCyp was confirmed by its 
inability to promote IgE reporter assay activation. Immunization with DNA or 
recombinant protein failed to induce protection in mice, although these formulations 
regulated liver granuloma area in immunized mice. However, an immunogenic epitope 
identified in the SmCyp sequence, namely SmCyp (107–121), induced a significant 
reduction in worm burden (48–50%), which was associated with the significant 
production of antibodies against this epitope. Our results indicated that SmCyp (107–
121) is a promising vaccine candidate.  
 
2. Materials and methods 
2.1 In silico characterization of SmCyp 
The S. mansoni cyclophilin A (access number: XP_018652799.1; Smp_040130.1) 
amino acid sequence was analyzed using SOSUI Engine version 1.11 
(http://harrier.nagahama-i-bio.ac.jp/sosui/sosui_submit.html) to predict transmembrane 
domains and solubility. EULOC (http://euloc.mbc.nctu.edu.tw/output.php), CELLO2 
(http://cello.life.nctu.edu.tw/) and PSORT II (https://psort.hgc.jp/form2.html) was used 
to predict cellular localization. SignalP4.1 (http://www.cbs.dtu.dk/services/SignalP/) 
was used to predict signal peptides in the protein sequence. The molecular weight and 
isoelectric point of SmCyp was predicted using the compute pi/MW tool 
(https://web.expasy.org/cgi-bin/capute_pi/pi_tool). To assess the similarity between 
human or helminthic proteins, the amino acid sequences were compared with the 
National Center for Biotechnology Information protein database using the BlastP 
(BLAST - Basic Local Alignment Search Tool) algorithm 
(blast.ncbi.nlm.nih.gov/Blast.cgi), with the default parameters of this algorithm.  
T cell and B cell epitope prediction was performed using Rankpep 
(http://imed.med.ucm.es/Tools/rankpep.html) and BCPred 
(http://ailab.ist.psu.edu/bcpred/), respectively. In Rankpep, T cell epitope prediction was 
performed using default parameters selecting IaB to predict C57BL-6 T cell epitopes in 
the protein sequence. While for BCPred, B cell epitope predictions were performed 
using Flexible Length Prediction (FLP) and 75% specificity. Potential SmCyp 
allergenicity was searched using the Allergen Online database 
(http://www.allergenonline.org/databasefasta.shtml) and full-length Fasta analysis.   
2.2. Model building and sequence alignment 
The amino acid sequence of S. mansoni SmCyp was retrieved from the NCBI database 
(Accession ID XP_018652799.1) and submitted to build a three-dimensional homology 
model by automated comparative modeling using Protein Homology/analogY 
Recognition Engine V 2.0 (Phyre2) using Intensive Modelling Mode (Kelley et al., 
2015). The resulting structure was predicted with 100% confidence with 96% sequence 
coverage (161 residues), or >90% confidence for 100% coverage. The resulting 
predicted image was generated using UCSF Chimera (v 1.13.1) Modeling software 
(Pettersen et al., 2004) 
Multiple amino acid sequence alignment of S. mansoni SmCyp (Accession ID 
XP_018652799.1), and S. mansoni cyclophilin A (Accession ID AAC47317.1) or S. 
mansoni SmCyp (Accession ID XP_018652799.1), Mus musculus, peptidyl-prolyl cis-
trans isomerase (Accession NP_032933.1), and Homo sapiens, peptidyl-prolyl 
isomerase A (Accession AAH05982.1) was performed using Clustal Omega (Sievers 
and Higgins, 2018) and EMBOSS Water was used for amino acid pairwise sequence 
alignment between S. mansoni SmCyp and P. falciparum chain A, peptidyl-prolyl cis-
trans isomerase.  
2.3 Mice and parasites 
All procedures performed using mice were approved by the FIOCRUZ’s Ethics 
Commission in animal use (CEUA) under the license numbers LW26/12.  C57BL/6 
mice (6–8-weeks-old) were purchased from the Instituto René Rachou (IRR) facility. 
The parasite life cycle (LE strain) was routinely maintained by passage through 
Biomphalaria glabrata snails and hamsters (Lombardo et al., 2019). Cercariae shedding 
was induced by exposing infected snails to light for 1–2 h and were provided by the 
Lobato Paraense snail facility from IRR.  
2.4 SmCyp recombinant protein expression 
The SmCyp synthetic gene containing the coding region sequence of SmCyp (access 
number:XP_002575376.1) was designed using ApE software (www.apesoftware.com).  
The mini-gene was designed with restriction sites for BamHI (GGATCC) at the 5′ end 
and XhoI (CTCGAG) followed by AgeI (ACCGGT) at the 3′ end. The gene encoding 
SmCyp was synthesized and cloned into the pIDT Smart cloning vector by IDT 
Technologies and subsequently subcloned into the bacterial expression vector pET28a 
TEV (Carneiro et al., 2006) using the BamHI and XhoI restriction sites and into the 
mammalian expression vector pcDNA 3.1 V5/His A (Invitrogen) using BamHI and 
AgeI restriction sites. The constructs were used to transform Escherichia coli 
BL21(DE3plys) and DH5α strains, respectively, and clones containing inserts were 
selected. The presence of the gene and its correct insertion into the plasmid were 
confirmed by sequencing. The expression of the 6 histidine-tag fusion protein in E.coli 
were induced with 1 mM isopropyl-B-D-galactopyranoside for 3 h at 37 °C with 
shaking at 250 rpm using BL21/PET28a TEV/SmCyp clones. The bacteria were lysed in 
a buffer (50 mM NaH2PO4, 0.3M NaCl, 40 mM imidazole) containing 1 µg/ml of 
lysozyme and 250 U of Benzonase Nuclease (Qiagen) for 30 min on ice. After 
centrifugation (14,000 x g, 30 min), the supernatant was used for the purification of 
recombinant protein, under native conditions, by affinity chromatography using the 
QIAexpress® Ni-NTA Fast Start Kit (Qiagen) according to the manufacturer’s 
instructions.  The pcDNA 3.1 V5/His A and pcDNA 3.1 V5/His A/Smcyp plasmid DNA 
purification was performed using EndoFree Plasmid Giga kit (Qiagen), according to 
manufacturer’s instructions. To confirm the production of rSmCyp in mammalian cells, 
the construct pcDNA 3.1 V5/His A/SmCyp was transfected into HEK293T cells using 
Lipofectamine 2000 (Invitrogen). The plasmid pcDNA 3.1 V5/His B, containing a non-
related gene with a C-terminal 6 His-tag was used as the positive control, and the 
empty plasmid pcDNA3.1/V5-His A and non-transfected cells were used as negative 
controls. In each well from a 24-well culture plate, 2.0  105 cells were seeded in 500μL 
of DMEM with 10% FBS. The plate was maintained at 37 °C and 5% CO2 for 24 h. 
Each sample of plasmid DNA (0.8 µg) and Lipofectamine 2000 (2 μL) was diluted 
separately in 50 µL of DMEM, and after a 5-min incubation at room temperature, the 
diluted Lipofectamine 2000 was mixed with each DNA sample. This mixture was 
incubated for 20 min at room temperature, facilitating the formation of DNA–liposome 
complexes. Each mixture was added to the cells, which were maintained for 
approximately 5 h at 37 °C in 5% CO2 and then washed in DMEM containing 10% 
FBS. After 48 h, transfected cultures were lysed for total protein extraction in 150 µL of 
2 Laemmli buffer (BioRad) with 5% β-mercaptoethanol. The samples were then boiled 
at 100 °C for 5 min and stored at −20 °C until use. The quality of the recombinant 
proteins obtained using bacteria and mammalian cells was analyzed by SDS-Page and 
Western blotting using an anti-6his tag monoclonal antibody (Ge Healthcare Life 
Sciences).  Briefly, protein samples were separated by SDS-PAGE (15%) and 
electrotransferred onto nitrocellulose blotting membranes (AmershamTM protran) at 300 
mA for 2 h on ice. Then membranes were blocked overnight with 5% skimmed milk 
powder in TBS (20mM tris, 500mM NaCl, pH7.5). To detect the fusion protein, the 
nitrocellulose membrane was probed with a mouse monoclonal anti-6×his tag antibody 
(1:3000; GE Healthcare Life Sciences) as the primary antibody, and subsequently 
incubated with HRP-conjugated goat anti-mouse IgG antibody (1:5000; Southern 
Biotech) as the secondary antibody. Immunoreactivity was detected with ECL Plus 
Western Blotting Detection System (GE Healthcare life sciences) and images were 
captured using ImageQuant LAS 4000 (GE Healthcare life sciences) by 
chemiluminescent method.  
2.5.  IgE Reporter system activation in vitro 
The ability of rSmCyp to promote IgE-mediated basophil activation degranulation was 
assessed using the humanized rat basophilic leukemia cell line (RS-ATL8 and NFAT-
DsRed reporters) as previously described (Wan et al., 2014b) with some modifications. 
Briefly, 1 × 105 cells/well were seeded in a white 96-well flat plate (RS-ATL-8 reporter) 
or a clear 96-well flat plate (NFAT-DsRed reporter); then, 50 µL of serum from 
individuals infected with Schistosoma mansoni (diluted 1:50) was added to each well. 
Then, cells were incubated for 16 h in a 37 °C/5% CO2 incubator.  Recombinant SmCyp 
was used to stimulate sensitized cells at three different concentrations (0.1, 0.001, and 
0.0001 µg/mL). Unstimulated sensitized cells were used as a negative control and anti-
human IgE antibody stimulation (1 µg/mL, goat-anti-human polyclonal, Merck) was 
used as a positive control. After 4 h of incubation with stimuli at 37 °C/5% CO2, 50 µL 
of ONE-Glo Luciferase substrate (Promega) was added to RS-ATL8 cells and 
luminescence was measured using Tecan Spark 10M multimode microplate reader. 
Each condition was analyzed in triplicates.  Fluorescence was observed in NFAT-
DsRed cells 24 h after stimulation using a fluorescence microscope (Evos FL Digital 
Inverted Fluorescence Microscope) at 10× magnification, 530 nm excitation, and 593 
nm emission. Receiver operating characteristic curves (ROC curves) were plotted to 
calculate the cutoff point, using the negative control (unstimulated cells) and the 
positive control (cells stimulated with anti-human IgE antibody). Samples of 
schistosomiasis patients were kindly provided by Colin Fitzsimmons and David Dunne. 
Samples used in this study are from a subgroup of participants of a study performed in 
Piida Village in Uganda described in Naus et al., 2003. Sixteen serum samples from 
individuals living in Piida Vilage (4 female/12 male), selected based on their high IgE 
antibodies levels against SmTal-1 or Swap, was used in this assay. Additionally, among 
the 16 sera analyzed, a pool of sera from individuals with the highest levels of IgE 
against SmTal-1 and another pool of sera from individuals with moderate levels of IgE 
against SmTal-1 were evaluated and treated as additional samples. The median epg 
determined by Kato-Katz in feces samples from these 16 individuals were 646.7 epg.    
2.6 Immunization of mice 
Female C57BL/6 mice (10 mice per group) were used for immunization protocols. For 
DNA vaccination, mice received four doses of 100 µg of purified DNA (pcDNA 3.1 
V5/His A or pcDNA 3.1 V5/His A/SmCyp) in the quadriceps muscle, with an interval of 
15 days between each dose. Five days before the first immunization, mice received 
50µL of cardiotoxin (10 µM)/quadriceps muscle. For rSmCyp, SmCyp (94–108) and 
SmCyp (107–121) peptide mixture, or SmCyp (107–121) immunization, mice were 
subcutaneously immunized with 25 µg of protein or 10 µg of synthetic peptides three 
times with a 15-day interval between each dose. Complete Freund’s adjuvant was used 
in the first immunization dose and incomplete Freund’s adjuvant was used for the 
following boosts. Physiological saline plus Freund’s adjuvant was used for control 
groups. Fifteen days after the last boost, mice were challenged through percutaneous 
exposure of the abdominal skin for 1 h to water containing 100 cercariae (LE strain) as 
described by Smithers and Terry (1965). Fifty days after challenge, adult worms were 
recovered by perfusion of the portal system and mesenteric veins according to 
Pellegrino and Siqueira (1956). The intestine and liver from each mouse were also 
collected 50 days post-infection. These organs were weighed and digested with 10% 
KOH for 16 h at 4 ºC and for 2 h at 37 ºC. The eggs were obtained by centrifugation at 
900 × g for 10 min and resuspended in 1mL of saline. Egg numbers were counted using 
a light microscope. Blood samples were collected from each mouse with an interval of 
15 days beginning 15 days after the first immunization. Serum samples were collected 
and stored at −20 ºC until use. Two independent experiments were performed.  
2.7 Measurement of hepatic granuloma area  
Liver sections of animals from control (pcDNA 3.1 V5/His A and Freund) and 
experimental groups (pcDNA 3.1 V5/His A/SmCyp, rSmcyp, and SmCyp (107–121) 
were collected 50 days post-infection to evaluate the effect of immunization on 
granuloma formation. The liver sections removed from the central part of the left lateral 
lobe were fixed in 10% buffered formaldehyde in PBS. Histological sections were 
obtained using a microtome and the slides were stained with hematoxylin and eosin 
(H&E). To perform area measurements, 100 granulomas from each group with a single 
well-defined egg at the exudative-productive stage were randomly selected and 
analyzed with a 10× objective lens using a JVC TK-1270/RGB microcamera. Using a 
digital pad, the total area of each granuloma was measured and the results were 
expressed as square micrometers (µm2).  
2.8. Measurement of specific antibodies levels 
The measurement of specific anti-SmCyp, anti-SmCyp (94–108), or anti-SmCyp (107–
121) IgG, IgG1 and IgG2c antibodies levels were performed by ELISA. MaxiSorp 96-
well microtiter plates (Nunc) were coated with 5 µg/mL (rSmCyp) or 1 µg/mL 
(peptides) of antigens in carbonate-bicarbonate buffer, pH 9.6, for 16 h at 4 ºC. The 
plates were then blocked for 2 h at 4 ºC with 300 µL/well of PBST (phosphate-buffered 
saline, pH 7.2 with 0.05% tween-20) plus 10% FBS (fetal bovine serum; GIBCO, 
USA). One hundred microliters of each serum sample diluted 1:50 in PBST was added 
per well and incubated for 1 h at room temperature. Plate-bound antibody was detected 
using 100 µL/well of a peroxidase-conjugated anti-mouse IgG (1:10,000), IgG1 
(1:2,000) or IgG2c (1:4,000) (Southern Biotech, USA). Color reactions were developed 
by adding 100 µL of TMB (Microwell Peroxidase Substrate System) per well and the 
reaction was stopped with 50 µL of 5% sulfuric acid per well. Absorbance was 
measured at 450 nm using an ELISA microplate reader. 
2.9 Statistical analysis 
GraphPad Prism 7.0 (Graph-Pad Software, San Diego, CA, USA) was used to perform 
statistical analyses. Normal distribution was tested using the Shapiro-Wilk normality 
test. ELISA analysis was performed using two-way ANOVA and Tukey’s multiple 
comparison test. Parasitological and histological analyses were performed using a 
Student’s t test. ROC curves were used to calculate the cutoff point, which was used to 
determine basophil activation of RS-ATL8 RBL cells stimulated with rSmCyp. Cutoff 
point determinations were based on the relative unit values of luciferase activity 
observed in the negative (RS-ATL-8 cells RBL + serum) and positive (RS-ATL-8 RBL 
cells + serum + anti-IgE) controls.  
3. Results 
3.1 Generation of recombinant SmCyp 
The SmCyp gene was inserted into a mammalian (pcDNA3.1V5/HIS A) and bacteria 
(pET28a TEV) expression vector as described in the methods section. Before starting 
the DNA immunization protocol, we evaluated SmCyp expression in mammalian cell 
cultures. Western blotting analysis of proteins extracts of HEK293T transiently-
transfected cells, using an antibody against the 6×His tag, demonstrated the successful 
expression of the rSmCyp with the expected molecular weight of 17.1 kDa (Fig. 1A).  
A recombinant form of SmCyp was also obtained using bacteria. Figure 1B 
demonstrates the electrophoretic profile of the purified rSmCyp with the expected 
molecular weight. Protein recognition by the 6×His tag monoclonal antibody (Fig 1C) 
indicated the production of rSmCyp in frame with the 6×His tag. This recombinant 
protein was used for immunization protocols and other assays (Fig 1C).   
3.2 SmCyp characterization  
The amino acid sequence of SmCyp (access number: XP_018652799.1) was used for 
bioinformatics analysis. SOSUI analysis indicated that SmCyp is a soluble protein with 
an average hydrophobicity of − 0.3434.  Protein localization predicted by EULOC, 
CELLO2 and PSORT II indicated that SmCyp is a cytoplasmic protein. Also, SinalP 4.1 
also indicated that this protein has no signal peptide, this result gives additional support 
to localization predictions.  SmCyp had a predicted molecular weight of 17,660 Da and 
a pI 8.26. BlastP analysis showed that this protein was similar to the peptidyl-prolyl cis-
trans isomerase from other helminths (Supplementary Table 1); among them, 
Schistosoma haematobium and S. japonicum, species that cause schistosomiasis in 
Africa and Asia, respectively. The SmCyp shares 67% sequence identity with mouse 
and 68% with human peptidyl-prolyl cis-trans isomerase (Supplementary Table 1 and 
Supplementary Figure 1  
To evaluate the structure of SmCyp, we performed homology modeling of SmCyp 
(XP_018652799.1) using the Phyre2. A three-dimensional model for SmCyp was 
successfully built with high confidence with Protein Homology/analogY Recognition 
Engine V 2.0 (Phyre2) using Intensive Modelling Mode. The resulting structure was 
predicted using six templates (4I9Y: e3 sumo-protein ligase ranbp2; 1VDN: Cyclophilin 
from Saccharomyces cerevisiae, variant A; 1W8M: Cyclophilin from Homo sapiens, 
variant A; 1IHG: bovine cyclophilin 40, 3K2C: peptidyl-prolyl cis-trans isomerase 2 
from Encephalitozoon cuniculi; 1XO7: Cyclophilin from Trypanosoma cruzithe bovine 
Cyclophilin 40 (PDB code: c1ihgA) with 100% confidence with 96% sequence 
coverage (161 residues), or >90% confidence for 100% coverage. 
The amino acids comprising the active sites for cyclophilins had been previously 
identified in another isoform of S. mansoni cyclophilin A (AAC47317.1), which had its 
three-dimensional structure solved by X-ray crystallography in reduced and oxidized 
states (Gourlay et al., 2007). To identify SmCyp active site amino acids, alignment was 
performed using S. mansoni cyclophilin A (AAC47317.1) and SmCyp 
(XP_018652799.1) amino acids sequences. The result showed that the amino acids 
sequences are closely related, and that the amino acids of the active site are conserved 
among them (Fig. 2B). The amino acids comprising the SmCyp active site are 
highlighted in the three-dimensional model of SmCyp (Fig. 2A). 
The T and B cells epitopes predicted by RankPep and BCpred with the highest scores 
are indicated in Figure 2B and Supplementary Table 2. Among the predicted epitopes, 
two regions, namely SmCyp (94–108) and SmCyp (107–121), contain T cell epitopes 
predicted with higher scores. As shown in the Figure 2A and B, the SmCyp (107–121) 
sequence comprises three of eight amino acids of the active site of SmCyp. In contrast, 
the SmCyp (94–108) sequence contains only one amino acid (ASN-99) of the SmCyp 
active site, but also contains an amino acid sequence that was predicted to be a B cell 
epitope (Supplementary Table 2). 
 
3.3 Assessment of potential rSmCyp allergenicity  
The cyclophilin family has been described as a pan-allergen (Flückiger et al., 2002). 
Therefore, we analyzed SmCyp allergenicity using the allergen online database based 
on the SmCyp full-length sequence. In this analysis, proteins that have a percent identity 
greater than 50% and an e-value score less than 1e-7 with a known allergen are likely to 
cause an allergic reaction. The results indicated that SmCyp could possibly cross-reacts 
with an allergen from Malassezia sympodialis, Der f Mal f 6 allergen from 
Dermatophagoides farinae, and with peptidylprolyl cis-trans isomerases from 
Aspergillus fumigatus, Catharanthus roseus, Daucus carota, and Betula pendula 
(Supplementary Table 3). 
To further evaluate rSmCyp allergenicity, we performed an in vitro assay using the 
humanized rat basophilic leukemia cell lines RS-ATL8 and NFAT-DsRed, as described 
(Wan et al., 2014a, 2014b). Even with different concentrations, rSmCyp was unable to 
activate basophils sensitized with IgE from sera of S. mansoni-infected individuals (Fig. 
3), since the luminescence detected in the reporter cell line stimulated with the 
recombinant protein was below the cutoff.  
3.4 Protective immunity induced by SmCyp immunization in mice 
To assess the ability of SmCyp to induce protection in a murine model, three different 
vaccine formulations (DNA immunization, recombinant protein, and synthetic peptide) 
were evaluated. Sera from mice immunized with a mixture of SmCyp (94–108) and 
SmCyp (107–121) showed higher levels of antibodies against SmCyp (107–121) but not 
SmCyp (94–108) (Supplementary Fig. 2); therefore, for immunization protocols we 
used a vaccine formulation containing only the synthetic peptide SmCyp (107–121).  
Immunization with pcDNA 3.1/His-A/SmCyp or rSmCyp neither significantly reduced 
the worm burden nor the number of eggs trapped in the intestine and liver (Table 1), but 
significantly reduced the area of liver granulomas (Fig. 4). In contrast, the vaccine 
formulation containing SmCyp (107–121) resulted in a significant reduction in worm 
burden (48-50%) and the number of eggs trapped in the liver (47-51%) and intestine 
(48%) (trial 2) (Table 1), but had no effect in pathology modulation (Fig. 4).   
3.5 Specific humoral immune response induced by vaccine formulations 
Antibody levels were measured in serum samples from animals immunized with the 
different vaccine formulations. In animals immunized with pcDNA 3.1/His-A/SmCyp 
significant production of antibodies against rSmCyp or SmCyp (107–121) was not 
observed (Fig. 5C and D). However, immunization with recombinant SmCyp induced a 
significant increase in the production of specific SmCyp IgG antibodies after the second 
and third immunization dose as compared to that in control and SmCyp (107–121) 
groups (Fig. 5A). In contrast, after the third vaccine dose, mice immunized with SmCyp 
(107–121) produced higher levels of anti-SmCyp (107-121) IgG antibodies when 
compared to those in control and rSmCyp groups (Fig. 5B).  
In the SmCyp (107–121) group, a significant increase in the levels of anti- SmCyp (107-
121) specific antibodies was observed after the second boost, whereas the rSmcyp group 
did not produce antibodies against this epitope. Although, an increase in the levels of 
anti-SmCyp specific IgG antibodies was observed in the rSmCyp group after the first 
boost with no additional production was induced by the second boost. 
Regarding IgG subclasses, mice immunized with rSmCyp produced significant levels of 
IgG1 and IgG2c against rSmCyp after the second and third immunization doses in 
comparison to the levels of these antibodies observed in Freund and SmCyp (107-121) 
groups (Fig 6 A and B). In animals immunized with SmCyp (107-121) peptide, after the 
third dose of the vaccine, increased levels of IgG1 and IgG2c antibodies against SmCyp 
(107-121) epitope were observed in comparison to the levels of antibodies observed in 
Freund and rSmCyp groups (Fig 6 C and D). In rSmCyp group, boosters induced an 
increase in the levels of IgG2c antibodies against this protein in comparison to the first 
dose of the vaccine (Fig 6 B). The first boost also increased the production of IgG1 anti-
rSmCyp in animals immunized with this recombinant protein, but, after the second 
boost, a decrease in the levels of these antibodies was observed (Fig 6 A).  In SmCyp 
(107-121) group, boosters increased the levels of IgG1 and IgG2c antibodies produced 
against SmCyp (107-121) epitope (Fig 6 C and D).   
 
 
 
4. Discussion 
Great efforts have been made to identify promising antigens and vaccine formulations 
against schistosomiasis. Among the already described S. mansoni vaccine candidates, 
including tetraspanin, Sm14, Smp80, and Sm29 (Tendler et al., 1996; Hota-Mitchell et 
al., 1997; Tran et al., 2006; Cardoso et al., 2008), cyclophilins have arisen as an 
interesting antigen for use in vaccine formulations, since this protein is the target of the 
schistosomicide drug cyclosporin A (Bueding et al., 1981). The demonstration that S. 
japonicum cyclophilin A induces a protective immune response in a murine model (Han 
et al., 2012) provided additional support for the use of this protein in vaccine 
formulations against S. mansoni.  Schistosomes produce different isoforms of 
cyclophilins, and in this study, we evaluated the ability of cyclophilin A (SmCyp), 
originally described by Kiang and coworkers as Smp17.7 (Kiang et al., 1996), to induce 
protection in mice when used as an antigen with different vaccine formulations and 
strategies.  
The characterization of this protein using in silico tools indicated that SmCyp is a 
soluble protein of approximately 18 kDa and is predicted to be a cytoplasmic protein. 
Immunolocalization assays identified SmCyp in the tegument, muscle layer, and gut 
epithelium of the S. mansoni (Kiang et al., 1996). The parasite tegument and gut 
epithelium represent the interface between the host and parasite (Wilson and Coulson 
2009). Many vaccine formulations containing antigens described as located in the 
tegument and gut were previously found to induce protection in mice (Fonseca et al., 
2012; Figueiredo et al., 2015).  
In the SmCyp sequence, the amino acids 94–122 are predicted to be a region containing 
T cell epitopes, whereas four B cell epitopes were predicted in different regions of the 
protein sequence (Supplementary Table 2 and Figure 2B). The three-dimensional 
structure of SmCyp obtained by computational modeling demonstrated that this protein 
has a β-barrel core (Fig. 2) structure similar to the canonical structure of cyclophilins 
(Gourlay et al., 2017). Among the amino acids that comprise the SmCyp active site, 
Asn-99, Phe-110, Trp-118, and Leu-199 are in a region of predicted epitopes. However, 
from the two synthetic peptides produced containing the amino acid sequences 94–108 
or 107-121, only SmCyp (107–121) was found to be immunogenic, since significant 
production of serum antibodies against this peptide was observed in mice immunized 
with a mixture of both peptides (Supplementary Fig. 2).  
Cyclophilins are well conserved among organisms.  SmCyp demonstrated high 
similarity to other cyclophilins, including cyclophilins from other helminths that infects 
humans, and also to the cyclophilin from mice and humans. Sharing epitopes with 
cyclophilins from other helminths could be an additional feature of SmCyp to be used 
as a vaccine candidate, since a vaccine containing this protein as an antigen could 
potentially protect against other helminthic parasites. However, the similarity to host 
proteins is not beneficial because the immune response to self-antigens is highly 
regulated and limits immune system activation upon vaccination (Bendle et al., 2005; 
Higgins et al., 2009). The poor immunogenicity observed for SmCyp (94–108) could be 
a consequence of the high-level of conservation of amino acids from this region 
between the parasite and the host (Mus musculus and Homo sapiens), as observed in 
Supplementary Figure 1. 
Some members of the cyclophilin family are described as allergens and cross-
recognition by anti-cyclophilin IgE has been observed among different species 
(Flückiger et al., 2002). Additionally, immunization with S. japonicum cyclophilin A 
induces a strong Th2 type immune response (Han et al., 2012), which could potentiate 
an allergic reaction. The use of potential allergenic antigens in vaccine formulations 
against helminths is a safety concern that needs to be addressed before moving forward 
to pre-clinical and clinical studies. An example of a promising vaccine that failed a 
phase I clinical trial due to generalized urticarial reactions induced post vaccination is 
the Necator americanus Na-ASP-2 (Diemert et al., 2012). In silico analysis of SmCyp 
suggests that this antigen is a potential allergen (Supplementary Table 3), but evaluation 
of the recombinant form of SmCyp in a functional in vitro assay failed to activate 
basophils sensitized with sera from individuals infected with S. mansoni (Fig. 3).  
Since SmCyp has characteristics of a good vaccine candidate, we evaluated this antigen 
using different formulations and vaccine strategies. In mice immunized with the gene 
encoding SmCyp, no significant reduction in the parasite burden or the number of eggs 
trapped in the liver and intestine was observed (Table 1). This lack of protection could 
not be attributed to unsuccessful expression of the protein in mammalian cells since in 
vitro assays demonstrated its production by HEK293T cells (Fig. 1). However, poor 
transfection efficiency in host cells of immunized mice could have impaired SmCyp 
production and resulted in a low vaccine immunogenicity accompanied by insignificant 
anti-SmCyp antibody production.   
The use of recombinant proteins together with a strong adjuvant might overcome the 
low immunogenicity observed after immunization with a DNA vaccine containing 
SmCyp. Adjuvants are key components of vaccine formulations that promote immune 
responses by recruiting professional antigen presenting cells (APCs) to the vaccination 
site, increasing the delivery of antigens to APCs, or activating cytokine production by 
APCs, which provides additional signals for T cell activation and differentiation 
(McKee et al., 2010). Indeed, mice immunization with recombinant SmCyp in 
association with Freund’s adjuvant resulted in the significant production of anti-SmCyp 
antibodies but failed to reduce parasite and egg burden. In contrast, the immunization of 
mice with a synthetic peptide containing the SmCyp (107–121) epitope significantly 
reduced worm burden and the number of eggs trapped in the liver (Table 1).  
Many studies have demonstrated the important role of humoral immune responses in the 
elimination of schistosome parasites. B cell-deficient mice vaccinated with radiation-
attenuated cercariae of S. mansoni showed significantly diminished protection against 
challenge infection when compared to that in wild-type vaccinated mice (Jankovic et al., 
1999). Moreover, serum transfer studies performed in rabbits, rats, and mice showed 
that serum from vaccinated animals could protect against S. mansoni infection when 
transferred to non-immunized recipients (Ford et al., 1984; Bickle et al., 1984; Torben 
et al., 2011; Melo et al., 2014). In our study, we observed a significant production of 
antibodies against SmCyp epitopes when mice were immunized with rSmCyp and 
SmCyp (107–121). However, only mice immunized with SmCyp (107–121) exhibited a 
protective immune response. These animals produced significantly higher levels of 
antibodies against the epitope containing amino acids 107–121. In contrast, mice 
immunized with the recombinant protein produced substantial levels of antibodies 
against other epitopes of the SmCyp protein, but not against SmCyp 107–121 epitope 
(Fig. 5).  
The evaluation of IgG subclasses in the sera from immunized mice, indicate that mice 
immunized with SmCyp (107-121) produce antibodies against this epitope of both IgG1 
and IgG2c subclasses. IgG1 antibodies in mouse are known to bind with high affinity to 
FcγRIIB, which is an inhibitor receptor and with low affinity to FcyRIII.  In contrast, 
IgG2c antibodies bind to FcγRI, FcγRIV and FcyRIII with high, intermediate and low 
affinity, respectively. In consequence, while IgG1 is a weaker inducer of ADCC and 
complement activation, IgG2c efficiently activate these immune effectors (Nimmerjohn 
and Ravetch, 2005; Bruhns and Jönsson, 2015) 
Different mechanisms of parasite elimination involve antibodies against targets in the 
parasite. Antibody-dependent cell mediated cytotoxicity (ADCC) is an important 
mechanism involved in Schistosoma elimination. In vitro studies demonstrated that 
ADCC is associated with schistosomula killing in mice immunized with 28-kDa 
glutathione S-transferase (GST) and Smp-80 (Balloul et al., 1987; Torben et al., 2012). 
Moreover, antibodies are involved in the reduction of female fecundity after GST 
immunization (Xu et al., 1991). In our study, the association of high levels of antibodies 
against the SmCyp 107–121 epitope and protection, suggests that these specific 
antibodies could block the enzymatic site of SmCyp, preventing peptidyl-prolyl cis-
trans isomerase activity and consequently resulting in the death of the parasites at some 
point during their development. However, ADCC active elimination of the parasite 
mediated by anti-SmCyp (107-121) IgG2c antibodies cannot be ruled out, and 
additional studies are necessary to determine which IgG subclass and effector 
mechanisms are involved in the protective immunity induced by SmCyp (107-121) 
epitope.   
A vaccine against schistosomiasis can act to eliminating the parasite, reducing its 
fecundity, or reducing the pathology associated with egg deposition in the liver. 
Therefore, we also evaluated liver pathology in mice immunized with different vaccine 
formulations containing SmCyp or one of its epitopes. The granulomatous reaction 
represents the major pathology associated with schistosomiasis, and the intensity of this 
reaction correlates with host morbidity (Wynn et al., 1995; Stadecker et al., 1998; Abath 
et al., 2006). In murine schistosomiasis, it has been shown that pathology is induced by 
CD4+ Th2 cells. These cells, through the production of IL-4 and IL-13, mediate the 
granulomatous response against schistosome eggs embedded in the host liver (Fallon et 
al., 2000; Wilson et al., 2007), whereas IL-10, IFN-γ, and inducible regulatory T-cells 
act to limit schistosome-induced pathology (Hesse et al., 2004). Analysis of the 
granulomatous response in immunized mice showed that immunization with the entire 
protein, as a DNA or recombinant protein subunit vaccine, significantly reduced the 
granuloma area. However, in mice immunized with the SmCyp (107–121) synthetic 
peptide, no significant reduction in granuloma area was observed (Fig. 4). Recently, 
Floudas and co-workers (2017) described some immunomodulatory proprieties of 
SmCyp (Smp17.7). They demonstrated that this protein modulates the production of 
pro-inflammatory cytokines by LPS-activated BMDCs (Bone Marrow-derived 
Dendritic cells), reduces T cell proliferation, and increases the proportion of CD4+ 
Foxp3+ regulatory cells (Floudas et al., 2017).  
Therefore, immunization with the SmCyp protein or gene would make the immune 
system prone to a modulatory profile that leads to changes in the granulomatous 
reaction, whereas immunization with the synthetic peptide SmCyp (107–121) induces a 
significant production of specific antibodies that target important amino acids of the 
active sites of this protein, potentially inhibiting protein activity and leading to parasite 
death.  The precise mechanisms of parasite elimination and granuloma modulation still 
require further clarification. However, our study demonstrates that SmCyp can regulate 
hepatic granuloma formation and we identified an epitope from this protein that could 
represent a target to induce a protective immune response against the parasite. The lack 
of activation of the RS-ATL8 IgE-reporter system suggests that this could be safe to 
use.  
 
Acknowledgements:  
We would like to thank David W Dunne, Colin M Fitzsimmons and Frances M Jones 
(University of Cambridge, UK) for kindly providing us with the sera from their 
Ugandan study in Piida. The authors thank the support of the Programa de Pós-
graduação em Ciências da Saúde, IRR. All Authors declare the absence of conflicts of 
interest 
Funding: This work was supported by Fundação de Amparo à Pesquisa do Estado de 
Minas Gerais/Programa de Pesquisa para o SUS- PPSUS: APQ-003478-13; Fundação 
de Amparo à Pesquisa do Estado de Minas Gerais/ Rede mineira de Imunobiológicos: 
RED00140-16; Conselho Nacional de Desenvolvimento Científico  e Tecnológico -
 Brasil (303711/2015-9); Coordenação de Aperfeiçoamento de Pessoal de Nivel 
Superior - Brasil (CAPES) - Finance Code 001 - PCDD Programa CAPES/Nottingham 
University (003/2014).  
Fellowships: FAPEMIG (MMM; CCA; GBC; DLFP); CNPq (TTM; VCF); Pq-CNPq 
(CTF; MMM); The Rosetrees Trust (K562) and Stoneygate Trust (MK); Islamic 
Development Bank- IDB (FG).  
 
. 
 
 
 
 
 
 
Legends:  
Figure 1 – Evaluation of recombinant Schistosoma mansoni cyclophilin A (SmCyp) 
expression in mammalian and bacterial systems. (A) SmCyp expression in 
mammalian cell cultures was evaluated by Western blotting, after the transient 
transfection of HEK293T cells, using an antibody against the 6His tag. Protein extracts 
of cells transfected with the pcDNA3.1/V5-His A plasmid containing the coding region 
of the SmCyp gene of S. mansoni fused to a 6His codon (lane 1), pcDNA3.1/V5-His B 
plasmid containing the coding region of a non-associated gene from S. mansoni fused to 
the 6His codon (lane 2), the empty pcDNA3.1/V5-His A plasmid (Lane 3), and non-
transfected cells (Lane 4) were analyzed. (B)  Recombinant SmCyp (rSmCyp) obtained 
in the bacterial system was evaluated by SDS-PAGE (15%) stained by Coomassie blue; 
Dual Color, BioRad Molecular weight marker (kDa) was loaded in lane 1 purified 
rSmCyp in lane 2. (C) Recognition of rSmCyp by the anti-6His tag monoclonal 
antibody was confirmed by Western blotting against the purified protein (Lane 1). 
Figure 2 – Predicted three-dimensional model of Schistosoma mansoni cyclophilin 
A (SmCyp). (A) Phyre2-predicted three-dimensional structure model of S. mansoni 
SmCyp based on six templates (4I9Y: e3 sumo-protein ligase ranbp2; 1VDN: 
Cyclophilin from Saccharomyces cerevisiae, variant A; 1W8M: Cyclophilin from 
Homo sapiens, variant A; 1IHG: bovine cyclophilin 40, 3K2C: peptidyl-prolyl cis-trans 
isomerase 2 from Encephalitozoon cuniculi; 1XO7: Cyclophilin from Trypanosoma 
cruzi) with 100% confidence. The active site amino acids (Arg-53, Phe-58, Met-59, 
Asn-99, Phe-110, Trp-118, Leu-199, and His-123) are shown in yellow, the predicted T 
cell epitope SmCyp (94–108) is colored pink, SmCyp (107–121) is colored green, C-
term GLU160 is red, and N-term ALA3 is blue. (B) Amino acid sequence alignment of 
S. mansoni SmCyp (Accession ID XP_018652799.1) and S. mansoni cyclophilin A 
(Accession ID AAC47317.1) was produced using Clustal Omega. The amino acids of 
the active site are highlighted in grey. The predicted B cell epitopes are shown in boxes. 
The predicted T cell epitope SmCyp (94–108) is indicated in bold, and SmCyp (107–
121) is indicated in italic bold. Identical residues are indicated by asterisks, conserved 
bases by double dots, and semi-conserved bases by single dots.   
Figure 3 – Evaluation of humanized basophils activation by recombinant 
Schistosoma mansoni cyclophilin A (rSmCyp).  NFAT-DsRed (A) and RS-ATL8 (B) 
IgE reporter systems cell strains were sensitized with sera from individuals infected 
with S. mansoni and stimulated with rSmCyp, using three different concentrations, 
specifically 0.1, 0.001, or 0.0001 µg/mL (gray circles), with 1 µg/mL of polyclonal goat 
anti-human IgE as a positive control (closed circles) or unstimulated cells as a negative 
control (open circles). (A) Representative images of NFAT-DsRed cells 24 h after 
stimulation. (B) Data represent relative luminescence unit values obtained for each 
condition.  Receiver operating characteristic curves (ROC curves) were used to 
calculate the cutoff point, using the negative (unstimulated cells) and positive (cells 
stimulated with anti-human IgE antibody) controls, which is denoted by the dotted line.  
Figure 4 – Hepatic granuloma in immunized mice. One hundred granulomas from 
each group with a single well-defined egg and at the exudative-productive stage were 
randomly selected and analyzed using a 10 objective lens (A). The total diameters of 
granulomas were measured, and the results are expressed as mean square micrometers 
(µm2) ± standard deviation (SD). Statistically significant differences are denoted in the 
graph based on p values. (B) Representative histological sections of liver granuloma.  
Figure 5 – IgG kinetics after mouse immunization. Mice were immunized with three 
doses of recombinant protein or synthetic peptide vaccine (A and B) or with four doses 
of DNA vaccine (C and D) and assessed to determine the kinetics of specific anti-
recombinant Schistosoma mansoni cyclophilin A (rSmCyp) (A and C) or anti-SmCyp 
(107–121) (B and D) IgG antibody production. Results represent the mean absorbance 
± SD measured at 450 nm. Significant differences between experimental and control 
groups are denoted by “a”; differences between rSmCyp and SmCyp (107–121) groups 
are denoted by “b”; * denotes significant differences compared to the first dose; # 
denotes significant differences compared to the second dose. 
Figure 6 –Kinetics of specific IgG 1 and IgG2c production after immunization with 
rSmCyp and SmCyp (107–121). Sera from immunized mice were assessed to 
determine the production of IgG1 (A and C) and IgG2c (B and D) specific to anti-
rSmCyp (A and B) or anti-SmCyp (107-121) (C and D). Results represent the mean 
absorbance + standard error of mean (SEM) measured at 450 nm. Significant 
differences between experimental and control groups are denoted by “a”; differences 
between rSmCyp and SmCyp (107-121) groups are denoted by “b”; * denote significant 
differences compared to the first dose; # denote significant differences compared to the 
second dose. 
Supplementary Figure 1 –Alignment of Schistosoma mansoni (Sm), Mus musculus, 
and Homo sapiens Cyclophilins. Schistosoma mansoni peptidyl-prolyl cis-trans 
isomerase (XP_018652799.1), Mus musculus peptidyl-prolyl cis-trans isomerase 
(NP_032933.1), and Homo Sapiens peptidylprolyl isomerase A (AAH05982.1) protein 
sequences were aligned using Clustal Omega. The region denoted by a solid line 
corresponds to the SmCyp (94–108) epitope and the region denoted by a dashed line 
represents the SmCyp (107–121) epitope. Identical residues are indicated by asterisks, 
conserved residues by double dots, and semi-conserved sites by single dots.   
Supplementary Figure 2 – IgG production in mice after immunization with a 
mixture of Schistosoma mansoni cyclophilin A (SmCyp) (94–108) and SmCyp 
(107–121). Blood samples from mice immunized with three doses of a mixture of 
SmCyp (94–108) and SmCyp (107–121) were assessed to determine the kinetics of 
specific anti-SmCyp (94–108) (A) or anti-SmCyp (107–121) (B) IgG antibody 
production. Results represent the mean absorbance ± SD measured at 450 nm. 
Significant differences between experimental and control groups are denoted by “a”; * 
denotes significant differences compared to the first dose; # denotes significant 
differences compared to the second dose. 
 
Table 1 – Protective immune response in immunized mice 
*Reduction of total worms of immunized group compared to control group. 
#Reduction of eggs in tissue (liver and intestine) of immunized group compared to control group. 
NS- Not significant. 
 
 Worm burden recovery  
 
Female 
Mean+SD 
 
Male 
Mean+SD 
 
Total 
Mean +SD 
 
% of 
protection* 
 
Egg/gram of 
liver 
Mean +SD 
 
% of 
reduction# 
 
Egg/gram of 
intestine 
Mean +SD 
 
% of 
reduction# 
DNA Vaccine         
Trial 1         
pcDNA 3.1 V5/His A 18+4 18+3 36+5  24803+3577  16467+4776  
pcDNA 3.1 v5/His A/SmCyp 17+5 20+4 37+8 (NS) 28504+12200 (NS) 14459+5534 12%(NS) 
Trial 2         
pcDNA 3.1 V5/His A 22+5 24+4 46+7  9859+2457  10226+5599  
pcDNA 3.1 v5/His A/SmCyp 20+7 24+5 44+10 4.3% (NS) 12420+5302 (NS) 6668+2521 35%(NS) 
Recombinant protein         
Trial 1         
PBS 16+8 18+11 33+18  12752+6195  24953+11787  
rSmCyp 15+7 19+7 34+14 (NS) 10883+4625 15%(NS) 25109+13440 (NS) 
Trial 2         
PBS 13+3 17+4 29+5  9303+7418  13468+1342  
rSmCyp 15+3 17+5 32+8 (NS) 12851+7325 (NS) 11543+6247 14%(NS) 
Synthetic peptide         
Trial 1         
PBS 12+2 13+2 25+3  16470+6075  8114+1335  
SmCyp (107-121) 5+5# 8+5 13+10 48%(p=0.02) 8019+5575 51%(p=0.03) 5984+5217 26%(NS) 
Trial 2         
PBS 9+4 9+4 18+8  11939+3764  9357+3037  
SmCyp (107-121) 5+3# 4+4# 9+7 50%(p=0.02) 6350+3173 47%(p=0.004) 4858+3813 48%(p=0.01) 
Supplementary Table 1: Cyclophilin similarity among helminth, Mus musculus, and Homo sapiens proteins  
Annotation Species Accession number Identity E-value 
Peptidyl-prolyl cis-trans isomerase Schistosoma haematobium XP_012795780.1 97% 2e -112 
Hypothetical protein Opisthorchis viverrini XP_009164024.1 73% 4e -80 
Cyclophilin A Clonorchis sinensis ADY88065.1 73% 2e -78 
Peptidyl-prolyl cis-trans isomerase Opisthorchis viverrini OON15904.1 71% 2e -77 
Peptidyl-prolyl cis-trans isomerase Fasciola hepatica PIS83942.1 72% 6e -76 
Cyclophilin Taenia solium AHL20246.1 70% 2e -75 
Peptidyl-prolyl cis-trans isomerase Echinococcus granulosus XP_024352953.1 70% 3e -75 
Peptidyl-prolyl cis-trans isomerase Spirometra erinaceieuropaei AFX73000.1 72% 6e -75 
Peptidylprolyl isomerase A Schistosoma japonicum CAX72371.1 69% 2e -74 
Expressed protein Echinococcus multilocularis CDS51549.1 70% 2e -73 
Peptidylprolyl isomerase A Schistosoma japonicum CAX72383.1 68% 3e -73 
SJCHGC06679 protein Schistosoma japonicum AAW25810.1 67% 1e -72 
Peptidylprolyl isomerase A Schistosoma japonicum CAX72379.1 71% 1e -70 
Peptidyl-prolyl cis-trans isomerase A Mus musculus NP_032933.1 68% 2e -68 
Peptidylprolyl isomerase A Homo Sapiens AAH05982.1 67% 2e -67 
 
 
 Supplementary Table 2: Predicted B and T cell epitopes in Schistosoma mansoni cyclophilin A (SmCyp) amino acid sequence 
 
B cell epitopes Position Score 
GGDFTNGDGTGGKS 62 1 
NDVPDTTRNFRELC 
SMANAGPNTNGSQF 
25 
96 
0.999 
0.999 
KKMESLGSTSGKPS 137 0.988 
T cell epitopes  
(Iab restricted) 
Position  Score  
SLSMANAGPNTNGSQ 
GSQFFITTVPCSWLD 
QFFITTVPCSWLDGK 
94 
106 
108 
16077 
13364 
10183 
   
 
 
 
 
 
 Supplementary Table 3: Cyclophilin allergenic predicted cross-reactivity 
Allergen Gi number Full-length     Fasta analysis 
identity E value 
Allergen from Malassezia sympodialis gi: 4138173 64.6% 2.8 e-39 
Der f Mal f 6 allergen from Dermatophagoides farina gi: 37958141 67.3% 5.6 e-42 
Peptidylprolyl cis-trans isomerases from Aspergillus 
fumigatus. 
gi: 5019414 57.4% 1.3 e-35 
Cyclophilin from Aspergillus fumigatus gi: 91680605 66.0% 8 e-41 
Cyclophilin from Catharanthus roseus gi: 1220142 60.8% 4.3 e-35 
Cyclophilin from Daucus carota gi: 373939374 61.7% 1.3. e-35 
Peptidylprolyl cis-trans isomerases from Betula pendula gi: 21886603 59.0% 9.7. e-34 
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